Search
Healthy Clinical Trials in Miami, FL
A listing of 19 Healthy clinical trials in Miami, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 19
The city of Miami, Florida, currently has 19 active clinical trials seeking participants for Healthy research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Pediatric IBD Study
Recruiting
Is your 2-17 year old living with Crohn's Disease or Ulcerative Colitis? A clinical trial is currently open to enroll
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
2-17-year-olds. Eligible participants will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Colitis
Ulcerative
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Featured Trial
NAD+ Aging Study
Recruiting
The HEALING Lab at the University of Rhode Island is seeking volunteers between the age of 40-80 for a NAD+ aging study. Participants will receive $300 for completing a 5-week study, which involves taking an oral supplement (either a sugar pill or NAD+ supplement) for 4 weeks between two in-person sessions. To participate in this study, you cannot be taking hormones, pregnant, or breastfeeding.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Inbody Validation Study
Recruiting
This study is being done to answer the following questions: Are the extracellular water and total body water measurements made by InBody Bioimpedance Analysis (BIA) devices accurate when compared to standard tests such as the dilution method and magnetic resonance imaging? Are clinical measurements of body composition related to strength and metabolic health?
Conditions:
Healthy
Featured Trial
Healthy Volunteers Needed for a Research Study!
Recruiting
Healthy volunteers wanted! Are you interested in advancing medical science? Join our clinical research study in Austin for 7 nights in-house. Earn $8,650 while helping advance medical knowledge. Sign up today!
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Participants
Featured Trial
Bipolar Study for Patients Aged 10 to 17
Recruiting
A new short-term study is enrolling children and teens (ages 10-17) with bipolar depression. To pre-qualify, participants must meet the following criteria:
- Male or female patients 10 to 17 years of age
- Have primary diagnosis of Bipolar I or Bipolar II Disorder
- Have a history of at least one manic or hypomanic episode
- Current major depressive episode is ≥ 4 weeks and less than 12 months in duration
- Male or female patients 10 to 17 years of age
- Have primary diagnosis of Bipolar I or Bipolar II Disorder
- Have a history of at least one manic or hypomanic episode
- Current major depressive episode is ≥ 4 weeks and less than 12 months in duration
Conditions:
Bipolar Disorder
Bipolar Depression
Bipolar I Disorder
Depression
Bipolar
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
Recruiting
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer.
The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Clinical Pharmacology of Miami ( Site 0002), Miami, Florida
Conditions: Hepatic Impairment, Healthy Participants
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
Recruiting
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function.
The study will also assess the safety and tolerability of the single dose of palovarotene.
Participants will be enrolled in stages and divided into three groups based on their liver function:
* Group 1: Healthy participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/27/2025
Locations: ERG - Clinical Pharmacology of Miami, Miami, Florida
Conditions: Hepatic Impairment, Healthy
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Recruiting
This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.
Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body wei... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
05/25/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy, Obesity
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Recruiting
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.
The study will last up to approximately 9 weeks, exclu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/23/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Liver Dysfunction, Healthy
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Recruiting
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/23/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy Participants
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
Recruiting
The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
05/23/2025
Locations: Advanced Pharma CR, LLC ( Site 0005), Miami, Florida
Conditions: Healthy
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
Recruiting
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/23/2025
Locations: Cpmi /Id# 274464, Miami, Florida
Conditions: Healthy Volunteer
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Recruiting
The purposes of this study are to determine:
* The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy, Hepatic Impairment
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Recruiting
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/14/2025
Locations: Neumora Investigator Site, Miami, Florida +2 locations
Conditions: Alzheimer's Disease, Healthy Elderly
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
Recruiting
The purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors (physical activity, dietary intake) among Hispanic female cancer survivors and adult daughters.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Cancer, Breast, Cancer, Uterus, Cancer, Ovary, Obesity, Activity, Motor, Diet, Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/17/2025
Locations: QPS-MRA, LLC ( Site 0012), Miami, Florida
Conditions: Healthy
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Recruiting
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Hepatic Insufficiency, Healthy
1 - 12 of 19